ELOCON Drug Patent Profile

Which patents cover Elocon, and when can generic versions of Elocon launch?

Elocon is a drug marketed by Organon and is included in three NDAs.

The generic ingredient in ELOCON is mometasone furoate. There are thirty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Elocon

A generic version of ELOCON was approved as mometasone furoate by PADAGIS US on March 18^th, 2002.

Summary for ELOCON

US Patents:	0
Applicants:	1
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	3
Patent Applications:	4,474
Drug Prices:	Drug price information for ELOCON
What excipients (inactive ingredients) are in ELOCON?	ELOCON excipients list
DailyMed Link:	ELOCON at DailyMed

See drug prices for ELOCON

Recent Clinical Trials for ELOCON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
LEO Pharma	Phase 1
University of Oulu	Phase 4
Merck Sharp & Dohme Corp.	Phase 4

See all ELOCON clinical trials

Paragraph IV (Patent) Challenges for ELOCON

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ELOCON	Topical Solution (Lotion)	mometasone furoate	0.1%	019796	1	2004-06-10

US Patents and Regulatory Information for ELOCON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	ELOCON	mometasone furoate	CREAM;TOPICAL	019625-001	May 6, 1987		DISCN	No	No
Organon	ELOCON	mometasone furoate	OINTMENT;TOPICAL	019543-001	Apr 30, 1987		DISCN	Yes	No
Organon	ELOCON	mometasone furoate	CREAM;TOPICAL	019625-002	Apr 19, 2013		DISCN	Yes	No

Expired US Patents for ELOCON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	ELOCON	mometasone furoate	OINTMENT;TOPICAL	019543-001	Apr 30, 1987	4,472,393*PED
Organon	ELOCON	mometasone furoate	CREAM;TOPICAL	019625-001	May 6, 1987	4,472,393*PED
Organon	ELOCON	mometasone furoate	LOTION;TOPICAL	019796-001	Mar 30, 1989	4,775,529*PED

International Patents for ELOCON

See the table below for patents covering ELOCON around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	820280
Norway	175762
Greece	3005762

Supplementary Protection Certificates for ELOCON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0057401	SPC/GB93/085	United Kingdom		SPC/GB93/085, EXPIRES: 20050621
0112669	96C0002	Belgium		PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
0057401	94C0002	Belgium		PRODUCT NAME: MOMETASONI FUROAS; NAT. REG.: 304 S 131 F 7 19930813; FIRST REG.: GR 10681/89 19900622

ELOCON Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Elocon (Mometasone Furoate)

Market Overview

Elocon, also known as mometasone furoate, is a potent corticosteroid widely used to treat various inflammatory skin conditions, including psoriasis, eczema, and dermatitis. The market for Elocon is influenced by several key factors that drive its growth and financial performance.

Growth Drivers

Increasing Prevalence of Chronic Conditions

The rising incidence of chronic skin conditions such as psoriasis, eczema, and dermatitis is a significant driver of the Elocon market. According to health statistics, a substantial portion of the population suffers from these conditions, contributing to the increasing demand for effective treatments like Elocon[3].

Advancements in Formulation Technology

Advancements in formulation technology have enhanced the efficacy and user experience of Elocon products. For instance, the development of topical creams, ointments, and nasal sprays has improved patient compliance and treatment outcomes, further driving market growth[3].

Growing Awareness of Skincare

Increasing awareness of skincare and overall well-being, particularly in developed regions, has led to higher demand for advanced skincare products, including those containing mometasone furoate. This trend is expected to continue, supporting market expansion[3].

Geographical Analysis

North American Market

North America is anticipated to capture a significant share of the Elocon market, driven by the high prevalence of skin conditions like psoriasis and eczema. The region's advanced healthcare infrastructure and high awareness of skincare products also contribute to its dominant market position[3].

European Market

The European market is another key region for Elocon, driven by approvals for various formulations of mometasone furoate and an aging population. The presence of e-commerce and online pharmacies in Europe has made it easier for patients to access these products, contributing to market growth[3].

Asia Pacific Market

The Asia Pacific region is expected to be the fastest-growing market for Elocon, fueled by the growing population of patients with inflammatory skin diseases and the increasing number of domestic manufacturers. This region offers significant opportunities for market expansion due to its large and growing patient base[3].

Financial Trajectory

Market Size and Growth

The global mometasone furoate market, which includes Elocon, is projected to reach USD 3 billion by 2036, growing at a CAGR of 7% during the forecast period from 2024 to 2036. In 2023, the market size was valued at USD 1 billion[3].

Revenue Projections

Another forecast indicates that the market will grow from $1.18 billion to $2.21 billion at a CAGR of 7.2% during the period from 2021 to 2030. This growth is driven by the increasing demand for effective treatments for chronic skin conditions[3].

Key Products and Sales Forecasts

Elocon (Mometasone Furoate)

Elocon, marketed by Merck & Co, is one of the leading products in the dermatological drugs market. The sales forecast for Elocon indicates continued growth, driven by its efficacy in treating various skin conditions. Detailed sales forecasts from 2020 to 2030 highlight the product's stable market position and potential for future growth[1].

Clinical Trials and Innovations

Lyra Therapeutics

Lyra Therapeutics is conducting pivotal Phase 3 clinical trials (ENLIGHTEN I and ENLIGHTEN II) to evaluate the efficacy and safety of LYR-210, which contains 7500µg of mometasone furoate, for the treatment of chronic rhinosinusitis (CRS). These trials aim to support a New Drug Application to the FDA and could expand the therapeutic applications of mometasone furoate[3].

Challenges and Restraints

Research and Development Costs

The increase in research and development expenses, as seen in companies like Lyra Therapeutics, can be a significant challenge. Higher clinical development costs and employee-related expenses are driving up R&D spending, which can impact the financial health of companies involved in the Elocon market[3].

Impairment Charges

Impairment charges related to long-lived assets can also impact the financial health of companies. These charges reflect potential overestimation of asset values or changes in the expected utility of these assets, which can affect the overall financial trajectory of the market[3].

Generic Competition

The entry of generic versions of Elocon can pose a challenge to the branded product. Generic competition can reduce market share and revenue for the original product, as seen with other dermatitis drugs like Protopic (tacrolimus)[1].

Leading Companies

Merck & Co

Merck & Co is one of the major players in the dermatological drugs market, including the Elocon product. The company's strong presence in the market, along with its research and development capabilities, positions it well for continued growth in the Elocon segment[1].

Other Key Players

Other leading companies in the dermatological drugs market include AbbVie, Allergan, Amgen, Bausch Health, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Galderma (Nestle Skin Health S.A.), GlaxoSmithKline (GSK), Johnson & Johnson, LEO Pharma, Novartis, and Pfizer. These companies play a crucial role in the overall market dynamics and financial trajectory of dermatological drugs, including Elocon[1].

Regional Market Analysis

North America

The North American market, particularly the U.S., is a significant segment for Elocon. Factors such as the legislative environment, including the impact of Obamacare repeal, and the stimulation of biosimilars, influence the market dynamics in this region[1].

Europe

Europe is another critical region, with countries like Germany, France, the UK, Italy, and Spain contributing to the market growth. The regional market shares and forecasts indicate that Europe will continue to be a vital market for Elocon[1].

Asia-Pacific

The Asia-Pacific region, including countries like China, Japan, and India, is expected to grow rapidly. The increasing population and rising awareness of skincare products drive the demand for Elocon in this region[1].

Market Outlook

Segment Growth

The dermatological drugs market, including the segment for Elocon, is expected to grow at a CAGR of 3.7% in the forecast period. The market is segmented by indication, including psoriasis, skin infection, acne, dermatitis, and others. Each segment's growth and revenue projections are critical for understanding the overall market outlook[1].

Competitive Landscape

The competitive landscape of the dermatological drugs market is characterized by a SWOT analysis and Porter’s Five Force analysis. These analyses provide insights into the strengths, weaknesses, opportunities, and threats faced by companies like Merck & Co, which markets Elocon[1].

Key Takeaways

• The Elocon market is driven by the increasing prevalence of chronic skin conditions, advancements in formulation technology, and growing awareness of skincare.
• North America and Europe are key regions driving market growth, with Asia Pacific emerging as a fast-growing market.
• Clinical trials and innovations, such as those by Lyra Therapeutics, are crucial for market expansion.
• Despite growth, the market faces challenges related to R&D costs and asset impairment charges.
• Generic competition and regulatory factors also influence the market dynamics.

FAQs

1. What is the projected market size of Elocon by 2036?

The global mometasone furoate market, which includes Elocon, is projected to reach USD 3 billion by 2036, growing at a CAGR of 7% during the forecast period from 2024 to 2036[3].

2. Which segment is expected to dominate the Elocon market?

The topical segment is expected to account for around 42% of the market share by 2036, driven by the surge in skin conditions like eczema, psoriasis, and dermatitis[3].

3. What are the key drivers of the Elocon market?

The key drivers include the increasing prevalence of chronic conditions, advancements in formulation technology, and growing awareness of skincare and overall well-being[3].

4. Which region is expected to capture the largest market share of Elocon?

North America is expected to capture over 47% of the Elocon market share by 2036[3].

5. What are the challenges faced by companies in the Elocon market?

The challenges include high research and development costs, impairment charges related to long-lived assets, and generic competition[3].

Sources

1. Visiongain: Dermatological Drugs Market Forecast 2020-2030.
2. Grupo Elecnor: Financial Results January-June 2024.
3. Drug Patent Watch: Mometasone furoate - Generic Drug Details.
4. Clarivate: Elocon / Fulmeta | 2022.
5. Elanco Animal Health: Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results.